Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis

Gang Lee^*
*Correspondence: Gang Lee, Department of Rheumatology and Immunology, University of West China Hospital, Sichuan, 37 Guoxue Xiang, Chengdu, Sichuan, China, Email:

Introduction

Osteoporosis is a multifactorial skeletal disorder characterized by low bone mass and micro architectural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures. It is a significant public health concern globally, particularly in aging populations. Identifying biomarkers associated with osteoporosis development is crucial for early diagnosis, risk assessment and targeted interventions. One promising biomarker is the Osteoprotegerin (OPG) gene, which plays a pivotal role in regulating bone remodeling and maintaining skeletal integrity.

Description

OPG is a glycoprotein encoded by the TNFRSF11B gene located on chromosome 8. It belongs to the Tumor Necrosis Factor (TNF) receptor superfamily and acts as a decoy receptor for the Receptor Activator of Nuclear Factor-kappa B ligand (RANKL). The RANKL/RANK/OPG axis is a key signaling pathway involved in the regulation of osteoclast formation, activation and survival. OPG competes with RANK for binding to RANKL, thereby inhibiting osteoclast differentiation and bone resorption. Consequently, OPG acts as a negative regulator of bone turnover and helps maintain bone mass and strength.

Genetic variations in the OPG gene have been extensively studied to elucidate their role in osteoporosis susceptibility. Single Nucleotide Polymorphisms (SNPs) within the OPG gene may alter OPG expression or function, thereby influencing bone metabolism and predisposing individuals to osteoporosis. Several OPG gene polymorphisms have been implicated in osteoporosis risk in different populations.

One of the most studied OPG polymorphisms is the G1181C SNP which is located in the promoter region of the OPG gene. This polymorphism has been associated with variations in OPG serum levels and Bone Mineral Density (BMD) in various ethnic groups. For instance, some studies have reported that the C allele of rs2073618 is associated with lower BMD and increased fracture risk in postmenopausal women, while others have found no significant association. Similarly, other OPG gene polymorphisms, such as T950C (rs3102735) and T245G (rs3134069), have been investigated for their potential role in osteoporosis susceptibility, although findings have been inconsistent across different populations [1,2].

The mechanisms underlying the association between OPG gene polymorphisms and osteoporosis risk remain incompletely understood. However, several hypotheses have been proposed to explain how genetic variations in the OPG gene may contribute to alterations in bone metabolism and predispose individuals to osteoporosis. Firstly, OPG gene polymorphisms may affect OPG expression levels, thereby influencing the balance between RANKL and OPG and subsequently modulating osteoclast activity and bone resorption. [3] For example, polymorphisms located in regulatory regions of the OPG gene may alter transcription factor binding affinity or mRNA stability, leading to changes in OPG production. Consequently, variations in OPG levels could disrupt bone homeostasis and contribute to osteoporosis development. Secondly, OPG gene polymorphisms may influence OPG protein structure or function, thereby affecting its ability to bind to RANKL and inhibit osteoclast genesis. Even subtle changes in OPG structure or ligand-binding affinity could impair its regulatory function and disrupt the RANKL/RANK/OPG signaling axis, leading to increased osteoclast activity and bone loss. Furthermore, OPG gene polymorphisms may interact with other genetic or environmental factors to modulate osteoporosis risk. For example, gene-gene interactions between OPG and other genes involved in bone metabolism, such as the RANK and RANKL genes, may synergistically influence bone remodeling processes and susceptibility to osteoporosis. Similarly, gene-environment interactions, such as hormonal status, nutritional factors, or physical activity levels, may modify the impact of OPG gene polymorphisms on bone health.

Understanding the role of OPG gene polymorphisms in osteoporosis pathogenesis has important clinical implications for risk assessment, early diagnosis and personalized management strategies. Genetic screening for OPG gene variants may help identify individuals at increased risk of developing osteoporosis, allowing for targeted interventions to prevent or mitigate bone loss and fracture risk. Furthermore, elucidating the underlying mechanisms linking OPG gene polymorphisms to osteoporosis may uncover novel therapeutic targets for pharmacological intervention [4].

However, several challenges and limitations need to be addressed in future research. Firstly, large-scale population-based studies with diverse ethnic cohorts are needed to validate the associations between OPG gene polymorphisms and osteoporosis risk and to elucidate the underlying mechanisms involved. Additionally, functional studies exploring the impact of OPG gene variants on OPG expression, protein function and bone metabolism are warranted to provide mechanistic insights into their role in osteoporosis pathogenesis. Moreover, prospective longitudinal studies are needed to assess the predictive value of OPG gene polymorphisms as biomarkers for osteoporosis risk and fracture outcomes over time [5].

Conclusion

The OPG gene represents a promising biomarker for assessing osteoporosis risk and understanding its underlying pathophysiology. Genetic variations in the OPG gene may contribute to alterations in bone metabolism, leading to imbalances in osteoclastogenesis and bone remodeling processes. Further research is needed to validate the clinical utility of OPG gene polymorphisms as biomarkers for osteoporosis risk stratification and to elucidate the mechanisms linking genetic variants to bone health. Ultimately, insights gained from studying the OPG gene may pave the way for the development of personalized approaches for osteoporosis prevention, diagnosis and treatment.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Sözen, Tümay, Lale Özışık and Nursel Çalık Başaran. "An overview and management of osteoporosis." Eur J Rheumatol 4 (2017): 46.

   Google Scholar, Crossref, Indexed at

2. Simonet, W.S., D.L. Lacey, C.R. Dunstan and M.C.M.S. Kelley, et al. "Osteoprotegerin: A novel secreted protein involved in the regulation of bone density." Cell 89 (1997): 309-319.

   Google Scholar, Crossref, Indexed at

3. Feng, Xu. "Ranking intracellular signaling in osteoclasts." IUBMB Life 57 (2005): 389-395.

   Google Scholar, Crossref, Indexed at

4. Arko, Barbara, Janez Preželj, Andreja Kocijančič and Radovan Komel, et al. "Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women." Maturitas 51 (2005): 270-279.

   Google Scholar, Crossref, Indexed at

5. Kostenuik, Paul J. "Osteoprotegerin a physiological and pharmacological inhibitor of bone resorption." Curr Pharm Des 7 (2001): 613-635.

   Google Scholar, Crossref, Indexed at